Myelofibrosis Transformation in Essential Thrombocythemia
Associated Genetic Biomarkers
NCI Definition: Myelofibrosis that develops in a patient with history of essential thrombocythemia. 
There are 3 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 2 are completed or closed. Of the trials that contain myelofibrosis transformation in essential thrombocythemia as an inclusion criterion, 1 is phase 1 (0 open) and 2 are phase 2 (1 open).
Pacritinib is the most common intervention in myelofibrosis transformation in essential thrombocythemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.